Press Releases
Gateway Genomics Joins Forces with Myriad Genetics to Further the Accessibility of Genetic Information to Consumers
With a focus on serving soon-to-be-parents through direct-to-consumer channels and participating medical locations, the company brings a sizeable consumer base and clinical network to Myriad Genetics’ prenatal and women’s health business.
Gateway Genomics Joins Forces with Myriad Genetics to Further the Accessibility of Genetic Information to Consumers
Gateway Genomics Ranks in the Inc. 5000 List of Fastest-Growing Companies for the Fourth Consecutive Year
With three-year revenue growth of 332%, the company ranked #1829 in the Inc. 5000 list for 2022.
Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces inclusion in the Inc. 5000 2022 list of fastest growing private companies for the fourth year in a row. To qualify, companies must have been founded and generating revenue by March 31, 2018. Ranking in the list is determined by the percentage revenue growth from 2018 to 2021, with minimums set for each year.
Gateway Genomics launches the only research-backed DNA test that provides fetal sex to pregnant mothers at 6 weeks gestational age
A breakthrough publication shows the SneakPeek Early Gender DNA Test predicted fetal sex accurately for 115 of 115 women recruited from 12 independent clinics across the US.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces a new peer-reviewed publication titled, “SneakPeek Early Gender Test: The Earliest and Most Accurate Method for Fetal Sex Determination at 6-Weeks’ Gestation” in the Clinics in Mother and Child Health journal.
Gateway Genomics Expands SneakPeek Clinical with Coast-to-Coast Coverage in Canada
International expansion continues to accelerate as healthcare providers sign on to offer the SneakPeek Gender DNA Test.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, achieved a milestone of over 130 distributors of its SneakPeek Clinical test in Canada, providing nationwide coverage for Canadians.
Gateway Genomics Surpasses 1500 Clinical Locations Across the US, UK, and Canada
Attracted by a science-based, accurate fetal sex test to acquire new clients and patients early in pregnancy, the number of clinical locations offering SneakPeek Gender DNA Test climbed in 2021.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, achieved a milestone of over 1,500 distributors of its SneakPeek Clinical test across the US, UK, and Canada. The rate of signup accelerated when the company added SneakPeek Snap to its clinical offerings.
Gateway Genomics Launches the Breakthrough SneakPeek Snap to All Clinical Partner Locations in the US
SneakPeek Snap is the first and only self-administered push-button device that makes it easy for parents to learn the gender of their babies with no more fingersticks or large needles.
Gateway Genomics, leading provider of direct-to-consumer genetic tests focused on prenatal and pediatric information, announces the launch of the new SneakPeek Snap into all clinical partner locations in the US. SneakPeek Snap is a microneedle-based device that collects capillary blood through the upper arm rather than through the fingertip or venipuncture, found to be completely painless by 90% of users in a recent clinical study. The automated, self-contained nature of SneakPeek Snap also makes it easy to self-administer; 90% of users in the same study found it very easy to use.
Gateway Genomics Surpasses 500,000 SneakPeek Early Gender DNA Tests Sold with Multiple Product Innovations in 2021
The sales milestone was achieved last month with accelerating sales for the company’s new SneakPeek Snap, which fully eliminates the need for fingerstick blood collection.
Gateway Genomics, leading provider of direct-to-consumer genetic tests focused on prenatal and pediatric information, reached 500,000 SneakPeek Early Gender DNA Tests sold last month, continuing the company’s rapid growth trajectory.
New Gateway Genomics Publication Shows SneakPeek Early Gender DNA Blood Test Accurately Identifies Fetal Sex at 7 Weeks into Pregnancy
In a large-scale study across 12 independent clinics, correct fetal sex results were provided for 125 out of 125 women at 7 weeks gestational age.
Gateway Genomics, leading provider of direct-to-consumer genetic tests focused on prenatal and pediatric information, announces a new publication titled, “Accurate Fetal Sex Determination from Maternal Blood at 7 Weeks Gestation” in the Journal of Pregnancy & Child Health. In the study, DNA blood samples were collected from 125 women at 7 weeks gestation across 12 independent clinics in the United States. Cell-free fetal DNA (cffDNA) was extracted and run through the SneakPeek test process, which looks for male chromosomes.
Gateway Genomics Earns Prestigious Mom’s Choice Award for SneakPeek Early Gender DNA Test as One of the Best Products for Families
An independent review panel received SneakPeek Gender test kits to evaluate, use, and score on elements including educational value, design, production quality, and cost.
Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces that the Mom’s Choice Award Among the Best in Family-Friendly Products was awarded to SneakPeek Gender DNA Test. To be considered for the award, five SneakPeek Gender DNA At-Home test kits were submitted for use to Mom’s Choice, which matched the products with appropriate evaluators in the MCA database.
Gateway Genomics Ranks 601 in the Inc. 5000 Fastest-Growing Private Companies in America List for 2021
For the third year in a row, Gateway Genomics was one of the fastest-growing private companies in the Health sector, which includes biotech, pharmaceutical firms, and makers of medical devices and products for the health care market.
Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces inclusion in the Inc. 5000 2021 list of fastest growing private companies for the third straight year. To qualify, companies must have been founded and generating revenue by March 31, 2017. Ranking in the list is determined by the percentage revenue growth from 2017 to 2020, with minimums set for each year.